The Company's first two product candidates employ NO containing nanoparticles. The Company's collaborators have published on the use of the Nitric Oxide (NO) containing nanoparticles as an antimicrobial treatment for Methycillin Resistant Staphylococcus aureus (MRSA) as well as Acinetobacter baumannii infected wounds and abscesses. 

Additional work has been conducted and published on the application of topical formulations delivering NO locally for the treatment of Erectile Dysfunction (ED) in patients refractory to currently available treatments.